Clinical Trial

mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 31, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, one-arm, phase II clinical study of intravenous mFOLFOX6 plus Camrelizumab combined with apatinib for CNLC stage III hepatocellular carcinoma
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT05412589
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Stage III Hepatocellular Cancer (CNLC Staging)
Enrollment 35 participants
Start Date 2022-06-10
Primary Completion 2025-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-31